Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in individuals with psoriasis.
The primary goals in the treatment of PsA are reduction of pain; improvement in the other
signs and symptoms of disease, including skin and nail involvement; optimization of
functional capacity and quality of life; and inhibition of the progression of joint damage.
These goals should be achieved while minimizing potential toxicities from treatment. The
management of PsA should simultaneously target arthritis, skin disease, and other manifestations
of PsA, including involvement of the axial skeleton, dactylitis, enthesitis, and eye
inflammation. In this respect targeted biological agents, primarily tumor necrosis factor
inhibitors, have emerged as generally well tolerated and highly effective alternatives to
traditional disease modifying antirheumatic drugs. Herein we review the evidence regarding
the treatment of PsA arthritis with biological agents.
Semin Cutan Med Surg 29:56-62 Published by Elsevier Inc.

Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in individuals with psoriasis.
The primary goals in the treatment of PsA are reduction of pain; improvement in the other
signs and symptoms of disease, including skin and nail involvement; optimization of
functional capacity and quality of life; and inhibition of the progression of joint damage.
These goals should be achieved while minimizing potential toxicities from treatment. The
management of PsA should simultaneously target arthritis, skin disease, and other manifestations
of PsA, including involvement of the axial skeleton, dactylitis, enthesitis, and eye
inflammation. In this respect targeted biological agents, primarily tumor necrosis factor
inhibitors, have emerged as generally well tolerated and highly effective alternatives to
traditional disease modifying antirheumatic drugs. Herein we review the evidence regarding
the treatment of PsA arthritis with biological agents.
Semin Cutan Med Surg 29:56-62 Published by Elsevier Inc.